Effect of Past Chlamydophila pneumoniae Infection on the Short-Time Mortality of COVID-19: A Retrospective Cohort Study.
antibody
chlamydophila pneumoniae
covid-19
persistent infection
retrospective cohort study
vascular disease
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
Feb 2023
Feb 2023
Historique:
accepted:
01
02
2023
entrez:
7
3
2023
pubmed:
8
3
2023
medline:
8
3
2023
Statut:
epublish
Résumé
Although In this retrospective cohort study, we examined 78 COVID-19 patients and 32 bacterial pneumonia patients who visited a tertiary emergency center in Japan between April 1, 2021, and April 30, 2022. CP antibody levels, including IgM, IgG, and IgA, were measured. Among all patients, the CP IgA-positive rate was significantly associated with age (P = 0.002). Between the COVID-19 and non-COVID-19 groups, no difference in the positive rate for both CP IgG and IgA was observed (P = 1.00 and 0.51, respectively). The mean age and proportion of males were significantly higher in the IgA-positive group than in the IgA-negative group (60.7 vs. 75.5, P = 0.001; 61.5% vs. 85.0%, P = 0.019, respectively). Smoking and dead outcomes were significantly higher both in the IgA-positive group and IgG-positive group (smoking: 26.7% vs. 62.2, P = 0.003; 34.7% vs. 73.1%, P = 0.002, dead outcome: 6.5% vs. 29.8%, P = 0.020; 13.5% vs. 34.6%, P = 0.039, respectively). Although the log-rank test revealed higher 30-day mortality in the IgG-positive group compared to the IgG-negative group (P = 0.032), Cox regression analysis demonstrated no significant difference between the IgG-positive and negative groups (hazard ratio (HR) = 4.10, 95%CI = 0.94-18.0, P = 0.061). The effect of past CP infection on 30-day mortality in COVID-19 patients was not obvious.
Sections du résumé
BACKGROUND
BACKGROUND
Although
METHODS
METHODS
In this retrospective cohort study, we examined 78 COVID-19 patients and 32 bacterial pneumonia patients who visited a tertiary emergency center in Japan between April 1, 2021, and April 30, 2022. CP antibody levels, including IgM, IgG, and IgA, were measured.
RESULTS
RESULTS
Among all patients, the CP IgA-positive rate was significantly associated with age (P = 0.002). Between the COVID-19 and non-COVID-19 groups, no difference in the positive rate for both CP IgG and IgA was observed (P = 1.00 and 0.51, respectively). The mean age and proportion of males were significantly higher in the IgA-positive group than in the IgA-negative group (60.7 vs. 75.5, P = 0.001; 61.5% vs. 85.0%, P = 0.019, respectively). Smoking and dead outcomes were significantly higher both in the IgA-positive group and IgG-positive group (smoking: 26.7% vs. 62.2, P = 0.003; 34.7% vs. 73.1%, P = 0.002, dead outcome: 6.5% vs. 29.8%, P = 0.020; 13.5% vs. 34.6%, P = 0.039, respectively). Although the log-rank test revealed higher 30-day mortality in the IgG-positive group compared to the IgG-negative group (P = 0.032), Cox regression analysis demonstrated no significant difference between the IgG-positive and negative groups (hazard ratio (HR) = 4.10, 95%CI = 0.94-18.0, P = 0.061).
CONCLUSION
CONCLUSIONS
The effect of past CP infection on 30-day mortality in COVID-19 patients was not obvious.
Identifiants
pubmed: 36879715
doi: 10.7759/cureus.34543
pmc: PMC9985306
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e34543Informations de copyright
Copyright © 2023, Horiuchi et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
Front Cell Infect Microbiol. 2022 Mar 21;12:843463
pubmed: 35386684
Int J Cardiol. 2007 May 31;118(2):215-9
pubmed: 17023075
BMJ Open. 2021 Oct 25;11(10):e052777
pubmed: 34697120
Nat Commun. 2020 Dec 9;11(1):6317
pubmed: 33298944
BMJ. 1999 Apr 17;318(7190):1035-9
pubmed: 10205100
J Infect. 2021 Apr;82(4):e4-e7
pubmed: 33482238
J Clin Pathol. 2002 Feb;55(2):115-7
pubmed: 11865005
Epidemiol Infect. 1995 Jun;114(3):465-73
pubmed: 7781734
Int J Mol Sci. 2021 Jun 21;22(12):
pubmed: 34205487
Respir Investig. 2020 Sep;58(5):336-343
pubmed: 32703757
Respir Investig. 2017 Nov;55(6):357-364
pubmed: 29153416
Ann Intern Med. 1992 Feb 15;116(4):273-8
pubmed: 1733381
Bull Natl Res Cent. 2022;46(1):115
pubmed: 35469122
Eur J Prev Cardiol. 2014 May;21(5):559-65
pubmed: 23253746
J Med Virol. 2022 Jan;94(1):303-309
pubmed: 34491594
Diagn Microbiol Infect Dis. 2022 Feb;102(2):115576
pubmed: 34800846
Nature. 2020 Aug;584(7821):430-436
pubmed: 32640463
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
Med Microbiol Immunol. 2011 Aug;200(3):143-54
pubmed: 21279651
BMJ. 2020 May 22;369:m1966
pubmed: 32444366
BMC Infect Dis. 2021 Aug 21;21(1):855
pubmed: 34418980
Trends Cardiovasc Med. 2021 Jan;31(1):1-5
pubmed: 33068723